BR112014004762A2 - métodos de determinação da sensibilidade de crescimento de célula tumoral á inibição por um inibidor de quinase de egfr, de identificação de um paciente com câncer que provavelmente irá se beneficiar do tratamento com um inibidor de efgr, de tratamento de um câncer em um paciente, de seleção de uma terapia para um paciente com câncer e de determinação de superexpressão de gene erbb2 em uma célula - Google Patents

métodos de determinação da sensibilidade de crescimento de célula tumoral á inibição por um inibidor de quinase de egfr, de identificação de um paciente com câncer que provavelmente irá se beneficiar do tratamento com um inibidor de efgr, de tratamento de um câncer em um paciente, de seleção de uma terapia para um paciente com câncer e de determinação de superexpressão de gene erbb2 em uma célula

Info

Publication number: BR112014004762A2
Authority: BR; Brazil
Prior art keywords: patient; determining; cancer; cancer patient; inhibitor
Prior art date: 2011-08-31

Application number

BR112014004762A

Other languages

English (en)

Inventor

Shames David

Januario Thomas

Original Assignee

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-08-31

Filing date

2012-08-30

Publication date

2018-06-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46826936&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014004762(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-08-30 Application filed by Genentech Inc filed Critical Genentech Inc

2018-06-19 Publication of BR112014004762A2 publication Critical patent/BR112014004762A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Immunology (AREA)
Zoology (AREA)
Analytical Chemistry (AREA)
Genetics & Genomics (AREA)
Pathology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Oncology (AREA)
Biophysics (AREA)
Microbiology (AREA)
Hospice & Palliative Care (AREA)
Molecular Biology (AREA)
Physics & Mathematics (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

BR112014004762A 2011-08-31 2012-08-30 métodos de determinação da sensibilidade de crescimento de célula tumoral á inibição por um inibidor de quinase de egfr, de identificação de um paciente com câncer que provavelmente irá se beneficiar do tratamento com um inibidor de efgr, de tratamento de um câncer em um paciente, de seleção de uma terapia para um paciente com câncer e de determinação de superexpressão de gene erbb2 em uma célula BR112014004762A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161529917P	2011-08-31	2011-08-31
PCT/US2012/053114 WO2013033380A1 (en)	2011-08-31	2012-08-30	Diagnostic markers

Publications (1)

Publication Number	Publication Date
BR112014004762A2 true BR112014004762A2 (pt)	2018-06-19

Family

ID=46826936

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR112014004762A BR112014004762A2 (pt)	2011-08-31	2012-08-30	métodos de determinação da sensibilidade de crescimento de célula tumoral á inibição por um inibidor de quinase de egfr, de identificação de um paciente com câncer que provavelmente irá se beneficiar do tratamento com um inibidor de efgr, de tratamento de um câncer em um paciente, de seleção de uma terapia para um paciente com câncer e de determinação de superexpressão de gene erbb2 em uma célula

Country Status (13)

Country	Link
US (4)	US20130084286A1 (pt)
EP (1)	EP2751285B2 (pt)
JP (1)	JP6297490B2 (pt)
KR (1)	KR20140057356A (pt)
CN (1)	CN104024432B (pt)
AU (1)	AU2012301889B2 (pt)
BR (1)	BR112014004762A2 (pt)
CA (1)	CA2845179A1 (pt)
IL (1)	IL230851A0 (pt)
MX (1)	MX2014002436A (pt)
RU (1)	RU2614254C2 (pt)
SG (1)	SG2014011316A (pt)
WO (1)	WO2013033380A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9984201B2 (en)	2015-01-18	2018-05-29	Youhealth Biotech, Limited	Method and system for determining cancer status
US11214838B2 (en) *	2016-06-10	2022-01-04	National Cancer Center	Method of predicting effect of medicinal therapy on cancer
EP3481403B1 (en)	2016-07-06	2022-02-09	Youhealth Biotech, Limited	Solid tumor methylation markers and uses thereof
BR112019018272A2 (pt)	2017-03-02	2020-07-28	Youhealth Oncotech, Limited	marcadores metilação para diagnosticar hepatocelular carcinoma e câncer
CN110511997A (zh)	2018-05-22	2019-11-29	广州市康立明生物科技有限责任公司	肿瘤标志物、甲基化试剂、试剂盒及其应用

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4018653A (en)	1971-10-29	1977-04-19	U.S. Packaging Corporation	Instrument for the detection of Neisseria gonorrhoeae without culture
US4016043A (en)	1975-09-04	1977-04-05	Akzona Incorporated	Enzymatic immunological method for the determination of antigens and antibodies
US4275149A (en)	1978-11-24	1981-06-23	Syva Company	Macromolecular environment control in specific receptor assays
US4318980A (en)	1978-04-10	1982-03-09	Miles Laboratories, Inc.	Heterogenous specific binding assay employing a cycling reactant as label
US4424279A (en)	1982-08-12	1984-01-03	Quidel	Rapid plunger immunoassay method and apparatus
US4737456A (en)	1985-05-09	1988-04-12	Syntex (U.S.A.) Inc.	Reducing interference in ligand-receptor binding assays
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US5208020A (en)	1989-10-25	1993-05-04	Immunogen Inc.	Cytotoxic agents comprising maytansinoids and their therapeutic use
US5183884A (en)	1989-12-01	1993-02-02	United States Of America	Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
SG64322A1 (en)	1991-05-10	1999-04-27	Rhone Poulenc Rorer Int	Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
JP4124480B2 (ja)	1991-06-14	2008-07-23	ジェネンテック・インコーポレーテッド	免疫グロブリン変異体
NZ243082A (en)	1991-06-28	1995-02-24	Ici Plc	4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
US6033854A (en)	1991-12-16	2000-03-07	Biotronics Corporation	Quantitative PCR using blocking oligonucleotides
AU661533B2 (en)	1992-01-20	1995-07-27	Astrazeneca Ab	Quinazoline derivatives
JPH08504172A (ja)	1992-06-30	1996-05-07	オンコロジクス，インコーポレイティド	抗−ｅｒｂＢ−２モノクロナール抗体の組み合わせ物及び使用方法
CA2103323A1 (en)	1992-11-24	1994-05-25	Gregory D. Plowman	Her4 human receptor tyrosine kinase
WO1995006137A1 (en)	1993-08-27	1995-03-02	Australian Red Cross Society	Detection of genes
CA2148931A1 (en)	1993-10-01	1995-04-13	Jurg Zimmermann	Pyrimidineamine derivatives and processes for the preparation thereof
US5656643A (en)	1993-11-08	1997-08-12	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
IL112248A0 (en)	1994-01-25	1995-03-30	Warner Lambert Co	Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
IL112249A (en)	1994-01-25	2001-11-25	Warner Lambert Co	Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
WO1995024190A2 (en)	1994-03-07	1995-09-14	Sugen, Inc.	Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
DK0682027T3 (da)	1994-05-03	1998-05-04	Ciba Geigy Ag	Pyrrolopyrimidinderivater med antiproliferativ virkning
EP2163546B1 (en)	1995-03-30	2016-06-01	Pfizer Products Inc.	Quinazoline derivatives
DE69609602T2 (de)	1995-04-03	2001-04-12	Novartis Ag, Basel	Pyrazolderivate und verfahren zu deren herstellung
GB9508538D0 (en)	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivatives
US5747498A (en)	1996-05-28	1998-05-05	Pfizer Inc.	Alkynyl and azido-substituted 4-anilinoquinazolines
US5650415A (en)	1995-06-07	1997-07-22	Sugen, Inc.	Quinoline compounds
TR199800012T1 (xx)	1995-07-06	1998-04-21	Novartis Ag	Piroloprimidinler ve preparasyon i�in tatbikler.
DK9500262U4 (da)	1995-07-07	1996-10-07	Bonus Energy As	Bundramme til vindmøllehus samt vindmølle omfattende samme
AR004010A1 (es)	1995-10-11	1998-09-30	Glaxo Group Ltd	Compuestos heterociclicos
GB9523675D0 (en)	1995-11-20	1996-01-24	Celltech Therapeutics Ltd	Chemical compounds
US5783186A (en)	1995-12-05	1998-07-21	Amgen Inc.	Antibody-induced apoptosis
JP4275733B2 (ja)	1996-01-23	2009-06-10	ノバルティスアクチエンゲゼルシャフト	ピロロピリミジンおよびその製造法
JP3406763B2 (ja)	1996-01-30	2003-05-12	東レ・ダウコーニング・シリコーン株式会社	シリコーンゴム組成物
GB9603097D0 (en)	1996-02-14	1996-04-10	Zeneca Ltd	Quinazoline compounds
GB9603095D0 (en)	1996-02-14	1996-04-10	Zeneca Ltd	Quinazoline derivatives
DE19608588A1 (de)	1996-03-06	1997-09-11	Thomae Gmbh Dr K	Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE19629652A1 (de)	1996-03-06	1998-01-29	Thomae Gmbh Dr K	4-Amino-pyrimidin-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
WO1997034895A1 (de)	1996-03-15	1997-09-25	Novartis Ag	NEUE N-7 HETEROCYCLYL-PYRROLO[2,3-d]PYRIMIDINE UND IHRE VERWENDUNG
DE69710712T3 (de)	1996-04-12	2010-12-23	Warner-Lambert Co. Llc	Umkehrbare inhibitoren von tyrosin kinasen
GB9607729D0 (en)	1996-04-13	1996-06-19	Zeneca Ltd	Quinazoline derivatives
US5786146A (en)	1996-06-03	1998-07-28	The Johns Hopkins University School Of Medicine	Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
CA2258548C (en)	1996-06-24	2005-07-26	Pfizer Inc.	Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
HRP970371A2 (en)	1996-07-13	1998-08-31	Kathryn Jane Smith	Heterocyclic compounds
ES2191187T3 (es)	1996-07-13	2003-09-01	Glaxo Group Ltd	Compuestos heteroaromaticos biciclicos como inhibidores de la proteina tirosin-quinasa.
EP0912559B1 (en)	1996-07-13	2002-11-06	Glaxo Group Limited	Fused heterocyclic compounds as protein tyrosine kinase inhibitors
ATE384062T1 (de)	1996-08-23	2008-02-15	Novartis Pharma Gmbh	Substituierte pyrrolopyrimidine und verfahren zu ihrer herstellung
ID18494A (id)	1996-10-02	1998-04-16	Novartis Ag	Turunan pirazola leburan dan proses pembuatannya
WO1998014449A1 (en)	1996-10-02	1998-04-09	Novartis Ag	Fused pyrazole derivatives and processes for their preparation
EP0929553B1 (en)	1996-10-02	2005-03-16	Novartis AG	Pyrimidine derivatives and processes for the preparation thereof
EP0837063A1 (en)	1996-10-17	1998-04-22	Pfizer Inc.	4-Aminoquinazoline derivatives
GB9621757D0 (en)	1996-10-18	1996-12-11	Ciba Geigy Ag	Phenyl-substituted bicyclic heterocyclyl derivatives and their use
KR20000070751A (ko)	1997-02-05	2000-11-25	로즈 암스트롱, 크리스틴 에이. 트러트웨인	세포 증식 억제제로서의 피리도[2,3-ｄ]피리미딘 및 4-아미노피리미딘
WO1999007701A1 (en)	1997-08-05	1999-02-18	Sugen, Inc.	Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
WO1999019488A1 (en)	1997-10-15	1999-04-22	Children's Medical Center Corporation	Novel human egf receptors and use thereof
ZA9811162B (en)	1997-12-12	2000-06-07	Genentech Inc	Treatment with anti-ERBB2 antibodies.
US6506559B1 (en)	1997-12-23	2003-01-14	Carnegie Institute Of Washington	Genetic inhibition by double-stranded RNA
RS49779B (sr)	1998-01-12	2008-06-05	Glaxo Group Limited,	Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
GB9800575D0 (en)	1998-01-12	1998-03-11	Glaxo Group Ltd	Heterocyclic compounds
AUPP249298A0 (en)	1998-03-20	1998-04-23	Ag-Gene Australia Limited	Synthetic genes and genetic constructs comprising same I
US6566131B1 (en)	2000-10-04	2003-05-20	Isis Pharmaceuticals, Inc.	Antisense modulation of Smad6 expression
US6410323B1 (en)	1999-08-31	2002-06-25	Isis Pharmaceuticals, Inc.	Antisense modulation of human Rho family gene expression
WO2000017339A1 (en) *	1998-09-18	2000-03-30	Kyowa Hakko Kogyo Co., Ltd.	Method for the diagnosis of cell proliferative disease
US6107091A (en)	1998-12-03	2000-08-22	Isis Pharmaceuticals Inc.	Antisense inhibition of G-alpha-16 expression
US5981732A (en)	1998-12-04	1999-11-09	Isis Pharmaceuticals Inc.	Antisense modulation of G-alpha-13 expression
US6046321A (en)	1999-04-09	2000-04-04	Isis Pharmaceuticals Inc.	Antisense modulation of G-alpha-i1 expression
US6331393B1 (en)	1999-05-14	2001-12-18	University Of Southern California	Process for high-throughput DNA methylation analysis
MXPA01011632A (es)	1999-05-14	2002-11-07	Imclone Systems Inc	Tratamiento de tumores refractarios humanos, con antagonistas de receptor del factor de crecimiento epidermico.
US6180349B1 (en)	1999-05-18	2001-01-30	The Regents Of The University Of California	Quantitative PCR method to enumerate DNA copy number
UA74803C2 (uk)	1999-11-11	2006-02-15	Осі Фармасьютікалз, Інк.	Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
GB9927444D0 (en)	1999-11-19	2000-01-19	Cancer Res Campaign Tech	Inhibiting gene expression
US7097840B2 (en)	2000-03-16	2006-08-29	Genentech, Inc.	Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
JP2003526367A (ja)	2000-03-16	2003-09-09	ジェネティカインコーポレイテッド	Ｒｎａ干渉の方法とｒｎａ干渉組成物
EP1282443B1 (en)	2000-05-19	2009-09-02	Genentech, Inc.	Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
US6365354B1 (en)	2000-07-31	2002-04-02	Isis Pharmaceuticals, Inc.	Antisense modulation of lysophospholipase I expression
US6566135B1 (en)	2000-10-04	2003-05-20	Isis Pharmaceuticals, Inc.	Antisense modulation of caspase 6 expression
US6441163B1 (en)	2001-05-31	2002-08-27	Immunogen, Inc.	Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
DE10130800B4 (de)	2001-06-22	2005-06-23	Epigenomics Ag	Verfahren zum Nachweis von Cytosin-Methylierung mit hoher Sensitivität
HRP20040529A2 (en) †	2001-12-12	2004-10-31	Pfizer Prod Inc	Quinazoline derivatives for the treatment of abnormal cell growth
US20050276812A1 (en)	2004-06-01	2005-12-15	Genentech, Inc.	Antibody-drug conjugates and methods
AU2003251597A1 (en)	2002-06-19	2004-01-06	Abgenix, Inc.	Method for predicting response to epidermal growth factor receptor-directed therapy
EP1534865A4 (en)	2002-06-26	2005-12-21	Cold Spring Harbor Lab	METHOD AND COMPOSITIONS FOR DETERMINING METHYLATION PROFILES
WO2004046386A1 (en)	2002-11-15	2004-06-03	Genomic Health, Inc.	Gene expression profiling of egfr positive cancer
JP2007520995A (ja)	2003-01-08	2007-08-02	ブリストル−マイヤーズ　スクイブ　カンパニー	上皮増殖因子受容体モデュレーターに対する感受性を決定するためのバイオマーカーおよび方法
EP1590487A2 (en)	2003-02-06	2005-11-02	Genomic Health, Inc.	Gene expression markers for response to egfr inhibitor drugs
JP4453297B2 (ja)	2003-05-27	2010-04-21	トヨタ自動車株式会社	車両用遊星歯車式多段変速機
AU2004248140A1 (en)	2003-05-30	2004-12-23	Cedars-Sinai Medical Center	Gene expression markers for response to EGFR inhibitor drugs
EP1664716A4 (en)	2003-08-15	2008-08-13	Smithkline Beecham Corp	CANCER BIOMARKERS
US7004206B2 (en)	2004-01-29	2006-02-28	Viken James P	Automatic fluid exchanger
CA2902980A1 (en) *	2004-03-08	2005-09-29	Rubicon Genomics, Inc.	Methods and compositions for generating and amplifying dna libraries for sensitive detection and analysis of dna methylation
JO3000B1 (ar)	2004-10-20	2016-09-05	Genentech Inc	مركبات أجسام مضادة .
KR101313702B1 (ko) *	2005-02-03	2013-10-04	와이어쓰	제피티니브 및/또는 에를로티니브 내성암 치료용 약제학적 조성물
ATE477495T1 (de)	2005-03-16	2010-08-15	Osi Pharm Inc	Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor
PE20070207A1 (es) *	2005-07-22	2007-03-09	Genentech Inc	Tratamiento combinado de los tumores que expresan el her
US7851154B2 (en) *	2005-07-22	2010-12-14	Simon Daniel Spivack	GC tag-modified bisulfite genomic DNA sequencing for continuous methylation spectra
WO2007067500A2 (en) †	2005-12-05	2007-06-14	Genomic Health, Inc.	Predictors of patient response to treatment with egfr inhibitors
WO2008027236A2 (en)	2006-08-30	2008-03-06	Genentech, Inc.	Multispecific antibodies
WO2009042618A1 (en) †	2007-09-24	2009-04-02	Tragara Pharmaceuticals, Inc.	Therapies for treating cancer using combinations of cox-2 inhibitors and anti-her2(erbb2) antibodies or combinations of cox-2 inhibitors and her2(erbb2) receptor tyrosine kinase inhibitors
US8841268B2 (en) *	2008-05-07	2014-09-23	Sapporo Medical University	Method and kit for detection of cancer, and therapeutic agent for cancer
CA2734905A1 (en)	2008-09-03	2010-03-11	Jenny M. Bostrom	Multispecific antibodies
ES2572728T3 (es)	2009-03-20	2016-06-02	F. Hoffmann-La Roche Ag	Anticuerpos anti-HER biespecíficos
CA2777906A1 (en) *	2009-10-28	2011-05-05	Signature Diagnostics Ag	Method for the prognosis of ovarian carcinoma

2012
- 2012-08-30 BR BR112014004762A patent/BR112014004762A2/pt not_active IP Right Cessation
- 2012-08-30 CN CN201280053486.4A patent/CN104024432B/zh active Active
- 2012-08-30 SG SG2014011316A patent/SG2014011316A/en unknown
- 2012-08-30 JP JP2014528597A patent/JP6297490B2/ja not_active Expired - Fee Related
- 2012-08-30 US US13/599,611 patent/US20130084286A1/en not_active Abandoned
- 2012-08-30 CA CA2845179A patent/CA2845179A1/en not_active Abandoned
- 2012-08-30 EP EP12756626.3A patent/EP2751285B2/en active Active
- 2012-08-30 AU AU2012301889A patent/AU2012301889B2/en not_active Ceased
- 2012-08-30 RU RU2014110895A patent/RU2614254C2/ru active
- 2012-08-30 MX MX2014002436A patent/MX2014002436A/es unknown
- 2012-08-30 WO PCT/US2012/053114 patent/WO2013033380A1/en not_active Ceased
- 2012-08-30 KR KR1020147007765A patent/KR20140057356A/ko not_active Abandoned
2014
- 2014-02-06 IL IL230851A patent/IL230851A0/en unknown
- 2014-11-24 US US14/551,528 patent/US20150086543A1/en not_active Abandoned
2017
- 2017-06-29 US US15/638,135 patent/US20170306419A1/en not_active Abandoned
2019
- 2019-10-02 US US16/591,253 patent/US11261498B2/en active Active

Also Published As

Publication number	Publication date
CN104024432B (zh)	2017-02-22
US20150086543A1 (en)	2015-03-26
RU2014110895A (ru)	2015-10-10
JP6297490B2 (ja)	2018-03-20
RU2614254C2 (ru)	2017-03-24
CA2845179A1 (en)	2013-03-07
JP2014525270A (ja)	2014-09-29
US20200024670A1 (en)	2020-01-23
EP2751285B1 (en)	2017-03-01
MX2014002436A (es)	2014-05-27
AU2012301889B2 (en)	2016-04-21
US11261498B2 (en)	2022-03-01
EP2751285B2 (en)	2020-04-01
AU2012301889A1 (en)	2014-03-06
US20130084286A1 (en)	2013-04-04
US20170306419A1 (en)	2017-10-26
SG2014011316A (en)	2014-06-27
WO2013033380A1 (en)	2013-03-07
EP2751285A1 (en)	2014-07-09
KR20140057356A (ko)	2014-05-12
HK1199475A1 (en)	2015-07-03
IL230851A0 (en)	2014-03-31
CN104024432A (zh)	2014-09-03

Publication	Publication Date	Title
EA201490230A1 (ru)	2014-06-30	Применение меченых ингибиторов hsp90
BR112012019459A2 (pt)	2017-10-17	identificação de mutação de lkb1 como um biomarcador preditivo para sensibilidade para inibidores de tor quinase.
BR112014023162A8 (pt)	2018-01-16	compostos e métodos para modulação quinase e indicações dos mesmos
EA201491584A1 (ru)	2014-12-30	Способы лечения немелкоклеточного рака легких c применением комбинированного лечения с ингибитором киназы tor
EA201390550A1 (ru)	2013-08-30	Способы ингибирования пролиферации клеток в egfr-стимулируемых злокачественных опухолях
MX338185B (es)	2016-04-05	Uso de anticuerpos anti-egfr en el tratamiento de enfermedad mediada por egfr mutante.
BR112016002000A2 (pt)	2017-08-29	Diagnóstico e terapia de câncer envolvendo células-tronco tumorais
BR112015008255A2 (pt)	2017-11-28	método para o diagnóstico, prognóstico e tratamento de metástase de câncer de próstata
EA201201474A1 (ru)	2013-08-30	Способы лечения рака молочной железы
BR112014011925A2 (pt)	2017-05-30	mutações no receptor notch humano e seu uso
BRPI0907637A8 (pt)	2018-01-02	biomarcadores p53
MX359227B (es)	2018-09-20	Tratamiento de cáncer con inhibidores de tor cinasa.
EA201491221A1 (ru)	2014-11-28	Новые молекулы, ингибирующие jnk, для лечения различных болезней
BR112012001395A2 (pt)	2019-09-24	metodo para tratar um câncer her2 positivo em um mamifero metodo para aumentar os efetivos de antagonistas do receptor her2 em um mamifero apresentando um cancêr her2 positivo metodo para inibir o crescimento ou proliferação de células her2 positivas em um mamifero
ES2721639T3 (es)	2019-08-02	Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama
PH12014502048B1 (en)	2020-10-28	Treatment of cancer with tor kinase inhibitors
CO7151491A2 (es)	2014-12-29	Método para la identificación del origen de un cancer de origen primario desconocido
BR112014012495A2 (pt)	2017-06-06	método in vitro, kit, inibidor de egfr e método de tratamento de pacientes afetados com câncer
NZ597292A (en)	2013-06-28	Use of PTP4A3 to predict a patient's response to treatment with an EGF receptor inhibitor
MX2013003076A (es)	2013-07-29	Terapeuticos contra cancer de mama.
BR112014004762A2 (pt)	2018-06-19	métodos de determinação da sensibilidade de crescimento de célula tumoral á inibição por um inibidor de quinase de egfr, de identificação de um paciente com câncer que provavelmente irá se beneficiar do tratamento com um inibidor de efgr, de tratamento de um câncer em um paciente, de seleção de uma terapia para um paciente com câncer e de determinação de superexpressão de gene erbb2 em uma célula
BR112013030606A2 (pt)	2016-12-13	biomarcadores para terapia inibidora de hedgehog
PH12014502046A1 (en)	2014-12-10	Treatment of cancer with tor kinase inhibitors
WO2012135714A3 (en)	2012-11-29	Serine biosynthesis pathway inhibition for treatment of cancer
TW201144807A (en)	2011-12-16	Identification, assessment, and therapy of cancers with innate or acquired resistance to ALK inhibitors

Legal Events

Date	Code	Title	Description
2018-06-26	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
2018-10-23	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2477 DE 26-06-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.